Opdivo, is a medication used to treat cancer. It is used as a first-line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma. We help patients and doctors get access to medicines at the lowest price worldwide.
|Oncology||Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer|
|Mode of Action||Monoclonal antibody (immunotherapy)|
|Regulatory agency approval||European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Pharmaceuticals and Medical Devices Agency (PMDA), Japan, Therapeutic Goods Administration (TGA), Australia|
|Strength||10 milligram / millilitre|